BR0111267A - Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda - Google Patents

Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda

Info

Publication number
BR0111267A
BR0111267A BR0111267-8A BR0111267A BR0111267A BR 0111267 A BR0111267 A BR 0111267A BR 0111267 A BR0111267 A BR 0111267A BR 0111267 A BR0111267 A BR 0111267A
Authority
BR
Brazil
Prior art keywords
nmda receptor
bicyclic
cyclohexylamines
receptor antagonists
formula
Prior art date
Application number
BR0111267-8A
Other languages
English (en)
Inventor
Russell Joseph Deorazio
Sham Shridhar Nikam
Ian Leslie Scott
Brian Alan Sherer
Lawrence David Wise
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0111267A publication Critical patent/BR0111267A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"CICLOEXILAMINAS BICìCLICAS E SEU USO COMO ANTAGONISTAS DO RECEPTOR DE NMDA". São descritas cicloexilaminas heterociclo-substituídas da fórmula (1) e seus sais farmaceuticamente aceitáveis das mesmas. Os compostos da fórmula (1) são antagonistas dos complexos do canal do receptor de NMDA úteis no tratamento de distúrbios vasculares cerebrais tais como, por exemplo, isquemia cerebral, ataque cardíaco, derrame e mal de Parkinson.
BR0111267-8A 2000-06-06 2001-05-14 Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda BR0111267A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20948500P 2000-06-06 2000-06-06
PCT/US2001/015605 WO2001094321A1 (en) 2000-06-06 2001-05-14 Bicyclic cyclohexylamines and their use as nmda receptor antagonists

Publications (1)

Publication Number Publication Date
BR0111267A true BR0111267A (pt) 2003-12-16

Family

ID=22778928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111267-8A BR0111267A (pt) 2000-06-06 2001-05-14 Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda

Country Status (11)

Country Link
US (1) US6683101B2 (pt)
EP (1) EP1292581B1 (pt)
JP (1) JP2003535851A (pt)
AT (1) ATE301642T1 (pt)
AU (1) AU2001263130A1 (pt)
BR (1) BR0111267A (pt)
CA (1) CA2407164A1 (pt)
DE (1) DE60112574T2 (pt)
ES (1) ES2243500T3 (pt)
MX (1) MXPA02010503A (pt)
WO (1) WO2001094321A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10210779A1 (de) * 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005085185A1 (en) * 2004-03-03 2005-09-15 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
WO2007063839A1 (ja) * 2005-11-30 2007-06-07 Shionogi & Co., Ltd. シクロヘキサン誘導体
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
ES2640814T3 (es) 2008-05-21 2017-11-06 Genesis Technologies Limited Inhibidores selectivos de caspasa y usos de los mismos
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
CN105153020A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种芳香叠氮化合物的制备方法
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239151A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
ATE239694T1 (de) * 1995-10-26 2003-05-15 Mitsubishi Pharma Corp Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP0982026B1 (en) 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
ATE326219T1 (de) * 1998-08-18 2006-06-15 Hoffmann La Roche Verwendung von aryl-cyclohexylamine derivaten zur herstellung von nmda-rezeptorblockern
MXPA02002749A (es) * 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.

Also Published As

Publication number Publication date
DE60112574D1 (de) 2005-09-15
MXPA02010503A (es) 2003-03-10
EP1292581A1 (en) 2003-03-19
DE60112574T2 (de) 2006-06-08
JP2003535851A (ja) 2003-12-02
CA2407164A1 (en) 2001-12-13
WO2001094321A1 (en) 2001-12-13
US6683101B2 (en) 2004-01-27
AU2001263130A1 (en) 2001-12-17
US20030232810A1 (en) 2003-12-18
ES2243500T3 (es) 2005-12-01
EP1292581B1 (en) 2005-08-10
ATE301642T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
BR0111267A (pt) Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda
BR0110247A (pt) Derivado de ciclohexilamina como antagonistas de receptor de nmda seletivos em subtipo
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
NZ522326A (en) Adenosine A2A receptor antagonists
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
BR0111301A (pt) Cicloexilaminas bicìclicas e seu uso como antagonistas de receptor de nmda
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
ME00017B (me) Derivati kamptotecina koji imaju antitumorno dejstvo
ATE413192T1 (de) Die vorbeugung und behandlung von netzhautischämie und ödem
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
UA83101C2 (en) 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0111279A (pt) Derivados da ciclohexilamina como antagonistas para o receptor do nmda seletivo ao subtipo
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
BR0113291A (pt) steres de aporfina e seu uso em terapia
SE9900961D0 (sv) Novel compounds
TR200102008T2 (tr) Serebral işemi profilaksı ve tedavisi için piridin türevlerinin kullanımı.
SE0002729D0 (sv) Novel compound form
BR0111055A (pt) Formulação farmacêutica, e, processo para a preparação e uso da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.